Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chlorthalidone vs. hydrochlorothiazide in hypertension management: Lessons for guiding clinical practice.

The American journal of the medical sciences·2026
Same author

Obesity-Related Hypertension: An Emerging Clinical Phenotype.

The American journal of cardiology·2026
Same author

Annotations from the latest guidelines for hypertension: A mixed bag of takes and mistakes.

The American journal of medicine·2025
Same author

High Heart Rate, Sympathetic Overdrive, and Cardiovascular Risk in Hypertension.

The American journal of cardiology·2025
Same author

Low-Salt Diet <i>and</i> Thiazide Diuretics.

Circulation·2025
Same author

Elevated Plasma Nitrate Levels in Patients with Acute Coronary Syndrome.

The American journal of cardiology·2025
Same journal

Acute Left Heart Failure in Twin Pregnancies: Clinical Characteristics and Outcomes-A 10‑Year Retrospective Analysis of 24 Cases.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Visit-to-Visit Systolic Blood Pressure Variability Predicts Long-Term Cardiovascular Events After Coronary Artery Bypass Grafting.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Blood Pressure Variability in Acute Ischemic Stroke: Current Evidence, Measurement Challenges, and Future Directions.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Association of Triglyceride-Glucose Index, Triglyceride/HDL Cholesterol Ratio and Metabolic Score for Insulin Resistance With Asymptomatic Organ Damage in Previously Untreated Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Calcium channel blockers.

William J Elliott1, C Venkata S Ram

  • 1Department of Preventive Medicine, Rush Medical College, Rush University, Chicago, IL, USA. welliott@rush.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|September 8, 2011
PubMed
Summary
This summary is machine-generated.

Calcium channel blockers effectively lower blood pressure in all patient groups and are approved for angina and cardiac dysrhythmias. While beneficial for cardiovascular disease, they are less effective than diuretics for heart failure.

More Related Videos

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
07:17

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels

Published on: December 13, 2024

Related Experiment Videos

Last Updated: May 29, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
07:17

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels

Published on: December 13, 2024

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Calcium channel blockers (CCBs) are a cornerstone in managing hypertension and cardiovascular diseases.
  • Their mechanism involves inhibiting calcium influx into vascular smooth muscle and cardiac cells, leading to vasodilation and reduced cardiac workload.

Purpose of the Study:

  • To provide practical recommendations on the use of calcium channel blockers based on current evidence.
  • To highlight their efficacy, limitations, and side effect profiles across diverse patient populations.

Main Methods:

  • Review of extensive comparative randomized trials and clinical experience.
  • Analysis of CCB efficacy in blood pressure reduction, cardiovascular event prevention, and specific conditions like angina and dysrhythmias.

Main Results:

  • CCBs effectively lower blood pressure across all demographics and are indicated for angina and cardiac dysrhythmias.
  • Nondihydropyridine CCBs offer negative chronotropic and inotropic effects beneficial for dysrhythmias and in conjunction with beta-blockers.
  • CCBs can prevent major cardiovascular diseases, except heart failure, where diuretics are superior. Dihydropyridine CCBs show less benefit in slowing renal disease progression compared to renin-angiotensin system inhibitors, though nondihydropyridines can reduce albuminuria.

Conclusions:

  • Calcium channel blockers are versatile agents for cardiovascular disease management, with specific subclasses offering distinct advantages.
  • Careful consideration of side effects, drug interactions, and specific patient conditions is crucial for optimal therapeutic outcomes.